Anavex Life Sciences develops oral small molecules that target SIGMAR1 and muscarinic receptors to mitigate cellular dysfunction in neurodegenerative and neurodevelopmental disorders. Its primary clinical program addresses Alzheimer’s disease while additional studies explore applications in Parkinson’s disease, Rett syndrome and other central nervous system conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -13.2 | — |
| Q3 2025 | 0 | — | -9.8 | — |
| Q4 2025 | 0 | — | -5.7 | — |
| Q1 2026 | 0 | — | -5.3 | — |
| Q2 2026 | 0 | — | 7.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: EDAP TMS S.A. (FOCL), Lexeo Therapeutics, Inc. (LXEO), GoPro, Inc. (GPRO), Ohio Valley Banc Corp. (OVBC), Limoneira Company (LMNR), Gesher Acquisition Corp. II (GSHR)